Why Is MODERNA INC (MRNA) Stock Up Today?

Moderna Inc (MRNA) stock rose 7.84% to $147.33 on Friday, driven by renewed investor interest in the company’s Phase 3 melanoma mRNA cancer therapy in collaboration with Merck. The stock’s sharp intraday swing reflected heightened volatility as the session opened at $136.19 and climbed to a high of $149.57 before settling near $147.41. The move followed a Seeking Alpha report highlighting the potential of the melanoma therapy and placed Moderna among the top S&P 500 gainers of the day.

What Happened

The rally was primarily fueled by news surrounding Moderna’s ongoing clinical trials for its melanoma mRNA therapy, which has generated optimism among investors. The therapy, developed in partnership with Merck, is seen as a potential breakthrough in the application of mRNA technology beyond vaccines. The Seeking Alpha article emphasized this development as a key catalyst for the stock’s performance. Meanwhile, the Motley Fool highlighted a broader debate between Moderna and Amgen, noting that while Moderna is valued much higher, it remains unprofitable and cash-burning. This contrast did not dampen enthusiasm for Moderna’s stock on the day, as the market focused on the therapeutic potential and the company’s high-beta profile.

What The Data Shows

The stock’s intraday movement was unusually volatile, with a session low of $135.01 and a high of $149.57. Trading volume reached 6.4 million shares, or 0.5 times the 3-month average, indicating moderate but not excessive participation. Over the past eight sessions, the stock has risen 3.7%, from $142.49 to $147.81. Options activity showed a heavy skew toward calls, with $11.5 million in call premiums compared to $157,000 in puts. The largest single options print was $3.3 million. Additionally, the stock hit a fresh 52-week high on the session, contributing to a broader market trend that saw 34 new 52-week highs for the day.

What To Watch

Moderna has no scheduled earnings release in the near term, but continued coverage of its melanoma therapy and related clinical updates will be key to monitoring the stock’s trajectory. Investors should also watch for further unusual options activity and any follow-up to recent congressional trades involving the stock.